Duopharma Biotech Berhad (KLSE: DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.180
0.00 (0.00%)
At close: Sep 6, 2024
Duopharma Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 748.03 | 704.73 | 696.72 | 639.18 | 569.9 | 576.46 | Upgrade
|
| Revenue Growth (YoY) | 7.32% | 1.15% | 9.00% | 12.16% | -1.14% | 15.59% | Upgrade
|
| Cost of Revenue | 478.9 | 436.4 | 416.9 | 385.19 | 336.7 | 344.4 | Upgrade
|
| Gross Profit | 269.13 | 268.33 | 279.82 | 253.98 | 233.2 | 232.07 | Upgrade
|
| Selling, General & Admin | 181.96 | 182.72 | 186.59 | 165.78 | 150.81 | 155.35 | Upgrade
|
| Other Operating Expenses | 2.59 | 2.8 | 0.81 | -0.67 | 1.35 | -0.52 | Upgrade
|
| Operating Expenses | 188.65 | 189.61 | 186.91 | 165.22 | 151.35 | 154.83 | Upgrade
|
| Operating Income | 80.48 | 78.71 | 92.91 | 88.77 | 81.86 | 77.23 | Upgrade
|
| Interest Expense | -24.34 | -17.68 | -9.1 | -6.44 | -6.53 | -7.96 | Upgrade
|
| Interest & Investment Income | 4.9 | 2.75 | 1.52 | 1.2 | 1.51 | 1.46 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.52 | -0.52 | -0.48 | -0.53 | -0.68 | 0.07 | Upgrade
|
| EBT Excluding Unusual Items | 60.52 | 63.27 | 84.85 | 82.99 | 76.16 | 70.81 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.01 | - | - | Upgrade
|
| Pretax Income | 60.52 | 63.27 | 84.85 | 82.98 | 76.16 | 70.81 | Upgrade
|
| Income Tax Expense | 11.08 | 10.62 | 14.74 | 17.3 | 17.55 | 15.54 | Upgrade
|
| Net Income | 49.44 | 52.65 | 70.11 | 65.68 | 58.61 | 55.27 | Upgrade
|
| Net Income to Common | 49.44 | 52.65 | 70.11 | 65.68 | 58.61 | 55.27 | Upgrade
|
| Net Income Growth | -28.02% | -24.91% | 6.74% | 12.07% | 6.04% | 16.02% | Upgrade
|
| Shares Outstanding (Basic) | 962 | 959 | 948 | 928 | 928 | 894 | Upgrade
|
| Shares Outstanding (Diluted) | 962 | 959 | 948 | 928 | 928 | 894 | Upgrade
|
| Shares Change (YoY) | 0.74% | 1.08% | 2.15% | 0.02% | 3.86% | 2.18% | Upgrade
|
| EPS (Basic) | 0.05 | 0.05 | 0.07 | 0.07 | 0.06 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.05 | 0.05 | 0.07 | 0.07 | 0.06 | 0.06 | Upgrade
|
| EPS Growth | -28.59% | -25.71% | 4.49% | 12.05% | 2.09% | 13.55% | Upgrade
|
| Free Cash Flow | 26.38 | 15.86 | 5.08 | -66.16 | 15.24 | 13.59 | Upgrade
|
| Free Cash Flow Per Share | 0.03 | 0.02 | 0.01 | -0.07 | 0.02 | 0.02 | Upgrade
|
| Dividend Per Share | 0.028 | 0.023 | 0.023 | 0.022 | 0.049 | 0.045 | Upgrade
|
| Dividend Growth | 21.74% | 0% | 5.75% | -55.43% | 8.44% | 8.96% | Upgrade
|
| Gross Margin | 35.98% | 38.08% | 40.16% | 39.74% | 40.92% | 40.26% | Upgrade
|
| Operating Margin | 10.76% | 11.17% | 13.34% | 13.89% | 14.36% | 13.40% | Upgrade
|
| Profit Margin | 6.61% | 7.47% | 10.06% | 10.28% | 10.28% | 9.59% | Upgrade
|
| Free Cash Flow Margin | 3.53% | 2.25% | 0.73% | -10.35% | 2.67% | 2.36% | Upgrade
|
| EBITDA | 119.57 | 114.04 | 122.86 | 114.94 | 105.93 | 100.52 | Upgrade
|
| EBITDA Margin | 15.98% | 16.18% | 17.63% | 17.98% | 18.59% | 17.44% | Upgrade
|
| D&A For EBITDA | 39.09 | 35.32 | 29.95 | 26.18 | 24.08 | 23.29 | Upgrade
|
| EBIT | 80.48 | 78.71 | 92.91 | 88.77 | 81.86 | 77.23 | Upgrade
|
| EBIT Margin | 10.76% | 11.17% | 13.34% | 13.89% | 14.36% | 13.40% | Upgrade
|
| Effective Tax Rate | 18.31% | 16.79% | 17.37% | 20.85% | 23.04% | 21.94% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.